Ingalls & Snyder LLC Makes New $233,000 Investment in iShares Biotechnology ETF (NASDAQ:IBB)

Ingalls & Snyder LLC bought a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,599 shares of the financial services provider’s stock, valued at approximately $233,000.

Several other hedge funds also recently made changes to their positions in IBB. Darwin Wealth Management LLC bought a new stake in shares of iShares Biotechnology ETF in the third quarter valued at approximately $29,000. Highline Wealth Partners LLC acquired a new stake in shares of iShares Biotechnology ETF during the 3rd quarter worth $30,000. Bbjs Financial Advisors LLC bought a new position in shares of iShares Biotechnology ETF in the second quarter worth $31,000. Ashton Thomas Securities LLC acquired a new position in iShares Biotechnology ETF in the third quarter valued at about $36,000. Finally, Voisard Asset Management Group Inc. bought a new stake in iShares Biotechnology ETF during the third quarter worth about $59,000. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Trading Down 1.2 %

Shares of iShares Biotechnology ETF stock opened at $140.00 on Wednesday. The firm’s 50-day moving average price is $142.63 and its two-hundred day moving average price is $142.12. iShares Biotechnology ETF has a 12-month low of $121.84 and a 12-month high of $150.57.

iShares Biotechnology ETF Announces Dividend

The company also recently disclosed a dividend, which was paid on Monday, September 30th. Investors of record on Wednesday, September 25th were paid a $0.2005 dividend. The ex-dividend date was Wednesday, September 25th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.